patient with neuroendocrine tumor on capecitibine and temozolomide chemotherapy presented with increased drowsiness difficult to rouse and feverish , is that a side effect of medicines if blood tests are all normal
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
capecitabine temozolomide neuroendocrine tumor neurotoxicity encephalopathy
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
capecitabine encephalopathy neurotoxicity
Reading File
Reading Article
Finding Sources
Finding Sources
Reading File
Reading Article
Searching PubMed
temozolomide encephalopathy altered consciousness CNS toxicity
I now have excellent data to give a thorough, clinically useful answer. Let me compile this.
Is This a Drug Side Effect? - Clinical Analysis
Short answer: Yes, this presentation can absolutely be caused by capecitabine, but it should NOT simply be attributed to the drugs until a full differential is worked up - especially because fever + decreased consciousness in a chemotherapy patient is a medical emergency until proven otherwise.
1. Capecitabine-Induced Neurotoxicity (Real and Well-Documented)
Yes - this is a recognized, albeit uncommon, complication of capecitabine. A 2022 systematic review and retrospective analysis of 24 cases (Ong et al., J Neurol Sci, PMID 36208584) found:
- Encephalopathy was the predominant symptom in 63% of cases (15/24 patients) - presenting exactly as drowsiness/reduced arousability
- Cerebellar ataxia in 42%
- MRI brain was abnormal in 78% of cases - typically leukoencephalopathy (white matter changes)
- Nearly all patients (96%) had complete resolution of neurological symptoms after stopping capecitabine
Another 2022 case report (Li et al., Am J Med Sci, PMID 35114182) described reversible toxic encephalopathy involving the cerebellum and subcortical white matter directly attributed to capecitabine, and highlighted an important mechanism:
The DPD Deficiency Mechanism (Critical)
Capecitabine is a prodrug that is converted to 5-fluorouracil (5-FU) in the body. About 80% of 5-FU is broken down by dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene. Patients with partial or complete DPD deficiency cannot clear 5-FU properly, leading to toxic accumulation and severe, dose-dependent toxicities including:
- Neurotoxicity / encephalopathy
- Myelosuppression
- Mucositis, diarrhea
- Hand-foot syndrome
(Katzung's Pharmacology, 16th Ed.) - This is a pharmacogenomic issue, not necessarily reflected in standard blood tests. If DPD testing was not done before starting capecitabine, this is a gap to address.
Uridine triacetate is an antidote that can be used in life-threatening 5-FU/capecitabine toxicity.
2. Temozolomide's Contribution
Temozolomide's documented CNS-relevant adverse effects include:
- Headache, fatigue, myelosuppression (Lippincott Pharmacology)
- As an alkylating agent, it can cause immunosuppression - which is critically relevant here (see below)
- It requires PCP (Pneumocystis pneumonia) prophylaxis because of the immunosuppression it causes
Temozolomide does not classically cause encephalopathy directly, but its immunosuppressive effect is a major contributor to infection risk.
3. "Blood Tests All Normal" - What Could Be Missed?
This is where clinical caution is essential. "Normal blood tests" typically means CBC, renal and liver function. But in this scenario, the following could still be abnormal or undetected:
| Investigation | What it catches | Notes |
|---|---|---|
| Blood cultures | Bacteraemia / sepsis | May be early - repeat at fever |
| Lumbar puncture / CSF | Meningitis, encephalitis | Normal bloods do NOT rule this out |
| MRI brain | Leukoencephalopathy (capecitabine), CNS metastases, PRES | Most sensitive test for capecitabine toxicity |
| EEG | Non-convulsive status epilepticus | Can cause unresponsiveness with normal labs |
| Blood glucose | Hypoglycaemia | Simple but can be missed |
| Ammonia | Hepatic encephalopathy | May be elevated even with "normal" LFTs |
| DPD activity / DPYD genotyping | Genetic cause of capecitabine toxicity | Not a routine blood test |
| Serum 5-FU levels | Direct toxicity monitoring | Specialist test |
| Thyroid function | Hypothyroidism | Can cause profound drowsiness |
| Cortisol | Adrenal insufficiency | Relevant if on dexamethasone or somatostatin analogues |
| Urine/sputum cultures, CXR | Occult infection | Temozolomide causes immunosuppression |
| Procalcitonin / CRP | Systemic infection/sepsis | More sensitive than WBC alone |
4. Differential Diagnosis - What Else to Consider
Given fever + decreased consciousness in a NET patient on chemotherapy:
- Capecitabine-induced toxic encephalopathy/leukoencephalopathy - drug toxicity, likely DPD-related
- Sepsis/neutropenic sepsis - temozolomide causes immunosuppression; fever + altered consciousness = infection until proven otherwise, even with a "normal" WBC (early sepsis can have a normal CBC)
- CNS infection (meningitis/encephalitis) - requires LP to exclude
- CNS metastases - NETs can metastasize to brain; worsening disease
- Carcinoid crisis - particularly in functional NETs; can cause haemodynamic instability and altered consciousness, though usually with flushing/hypotension
- Hypoglycaemia - insulinomas and other functional NETs
- Non-convulsive status epilepticus - requires EEG
- PRES (Posterior Reversible Encephalopathy Syndrome) - associated with chemotherapy
Immediate Clinical Action Points
- Do NOT reassure and discharge - this is a potentially serious presentation
- MRI brain - highest priority to look for leukoencephalopathy, metastases, PRES
- LP - if no contraindication, to exclude CNS infection
- Blood and urine cultures + broad-spectrum antibiotics if sepsis is suspected
- Stop or hold capecitabine pending investigation - if drug toxicity is the cause, this is the most important intervention and prognosis is excellent with early cessation
- Check DPD status (DPYD genotyping or phenotyping) - if not already done
- Consider uridine triacetate if life-threatening 5-FU toxicity confirmed
- Neurology consult for encephalopathy workup
Summary
Yes, capecitabine can cause this exact picture - encephalopathy with drowsiness and reduced arousability is its most common neurological manifestation. However, fever is not a typical feature of capecitabine-induced encephalopathy alone, and its presence must raise concern for sepsis or CNS infection, especially given the immunosuppressive effects of temozolomide. Normal standard blood tests do not rule out CNS infection, capecitabine leukoencephalopathy, or early sepsis. The most important next steps are MRI brain, LP, and holding capecitabine while investigating.
References:
- Ong et al., "Capecitabine related neurotoxicity: Clinical and radiologic features," J Neurol Sci 2022 [PMID: 36208584]
- Li et al., "Reversible Toxic Encephalopathy Involving the Cerebellum and Subcortical White Matter Attributed to Capecitabine," Am J Med Sci 2022 [PMID: 35114182]
- Katzung's Basic and Clinical Pharmacology, 16th Ed. - DPD Deficiency section
- Lippincott Illustrated Reviews Pharmacology - Temozolomide adverse effects
can temozolomide worsen side effects of capox
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
capecitabine temozolomide CAPTEM neuroendocrine toxicity adverse effects
Reading Article
Reading Article
Finding Sources
Finding Sources
Reading File
Reading File
Excellent data. I now have everything needed for a thorough, evidence-based answer.
Can Temozolomide Worsen the Side Effects of Capecitabine?
Yes - and this is well-characterized in clinical data. The combination (CAPTEM) produces both overlapping and synergistic toxicities across several organ systems. Here is a breakdown:
1. Clarification on Terminology
The regimen used in NETs is CAPTEM (capecitabine + temozolomide), not CAPOX. CAPOX is capecitabine + oxaliplatin (used for colorectal cancer). If your patient is on a NET regimen, it is almost certainly CAPTEM.
2. Where Temozolomide Amplifies Capecitabine Toxicity
A. Myelosuppression (Additive - Most Clinically Significant)
Both drugs suppress the bone marrow, but via different mechanisms:
- Capecitabine (via 5-FU) causes bone marrow suppression - particularly after short infusion-equivalent schedules, predominantly affecting neutrophils and thrombocytes (Harrison's, 22nd Ed.)
- Temozolomide causes myelosuppression (thrombocytopenia and neutropenia are dose-limiting), with a characteristic delayed nadir at around 21-28 days
Combined, the CAPTEM meta-analysis (Lu et al., Medicine 2018, PMID 30313101, 384 patients across 15 studies) reported:
- Grade 3-4 thrombocytopenia: 3.36%
- Grade 3-4 neutropenia: 0.69%
- Grade 3-4 lymphopenia: 0.65%
- Grade 3-4 anemia: 0.59%
The large Moffitt series (Al-Toubah et al., JNCCN 2021, PMID 34433130, 462 patients) found:
- Grade 4 thrombocytopenia in 7%
- Grade 4 neutropenia in 3%
- Women had significantly higher rates of severe cytopenias than men (p=0.02 and p=0.004)
- 3 patients developed myelodysplastic syndrome (all had prior PRRT)
Clinical implication: Even if the CBC looks "normal" right now, the nadir may not have occurred yet. The myelosuppression from CAPTEM can be delayed and severe.
B. Immunosuppression - The Most Dangerous Combination Effect
This is where temozolomide substantially amplifies capecitabine risk:
- Temozolomide causes profound T-cell-mediated lymphopenia - specifically depleting CD4+ lymphocytes
- This is so significant that PCP (Pneumocystis pneumonia) prophylaxis is explicitly recommended for all patients on temozolomide, and should continue until lymphopenia resolves, potentially for >6 months after stopping (Goldman-Cecil Medicine, Table 313-2)
- Capecitabine adds further immunosuppression on top of this
Fever + drowsiness in an immunosuppressed patient on CAPTEM must be treated as possible opportunistic infection until proven otherwise - including PCP, fungal infections, viral reactivation (CMV, HSV), and bacterial sepsis. The Moffitt series reassuringly found only 1 suspected PCP case (0.2%), but that patient was also on corticosteroids - meaning the risk is low but not zero.
C. Neurotoxicity (Potentially Additive)
- Capecitabine independently causes toxic encephalopathy (see previous discussion) via 5-FU accumulation, particularly in DPD-deficient patients
- Temozolomide is documented to cause headache, fatigue, and CNS-related symptoms (Lippincott Pharmacology)
- The pharmacological rationale for CAPTEM synergy is relevant here: capecitabine upregulates thymidine phosphorylase in tumor cells, which depletes MGMT (O6-methylguanine-DNA methyltransferase), making cells more susceptible to temozolomide's alkylating damage. This same biochemical interaction occurs in normal neural tissue and may amplify CNS toxicity when both drugs are given together.
Harrison's 22nd Ed. specifically notes that 5-FU (the active form of capecitabine) can cause CNS dysfunction with prominent cerebellar signs as a less frequent but recognized toxicity.
D. GI Toxicity (Additive)
Both drugs cause nausea, vomiting, diarrhea, and mucositis. The combination produces higher rates than either alone. Grade 3-4 mucositis and diarrhea are reported in ~0.5-1% of CAPTEM patients (Lu et al.).
E. Hepatotoxicity
Both drugs can elevate transaminases. Temozolomide has rare hepatotoxic potential; 5-FU causes reversible transaminase rises. Combined, monitoring is important.
3. Summary Table
| Toxicity | Capecitabine alone | Temozolomide alone | CAPTEM combined |
|---|---|---|---|
| Myelosuppression | Yes (neutropenia dominant) | Yes (thrombocytopenia dominant, delayed) | Additive - both cell lines affected |
| Immunosuppression / lymphopenia | Mild | Significant (CD4+ depletion) | Amplified - PCP prophylaxis required |
| Encephalopathy | Yes (DPD-related, leukoencephalopathy) | Headache, fatigue | Potentially additive |
| Nausea/vomiting/diarrhea | Yes | Yes | Additive |
| Hepatotoxicity | Mild transaminase rise | Rare | Monitor |
| Infection risk | Mild | Significant | High - opportunistic infections possible |
4. Bottom Line for This Patient
A patient on CAPTEM presenting with fever + decreased consciousness faces a combination of two risk factors working together:
- Capecitabine - direct cause of encephalopathy (leukoencephalopathy), especially if DPD-deficient
- Temozolomide - the immunosuppressive driver that opens the door to opportunistic infections explaining the fever
The two drugs together create a scenario where both direct drug toxicity AND infection-driven encephalopathy are live possibilities simultaneously - and both need to be ruled out urgently. "Normal blood tests" are insufficient to exclude either mechanism.
References:
- Lu et al., "Safety and efficacy of CAPTEM to treat advanced neuroendocrine neoplasms," Medicine 2018 [PMID: 30313101] - Meta-Analysis
- Al-Toubah et al., "Efficacy and Toxicity Analysis of CAPTEM in Neuroendocrine Neoplasms," JNCCN 2021 [PMID: 34433130] - 462 patients
- Harrison's Principles of Internal Medicine, 22nd Ed. - 5-FU/capecitabine toxicity
- Goldman-Cecil Medicine - PCP prophylaxis table (temozolomide)
- Lippincott Illustrated Reviews: Pharmacology - Temozolomide adverse effects
This is a shared conversation. Sign in to Orris to start your own chat.